Which medication is commonly used to treat Mycobacterium avium complex infection in HIV patients?

Which medication is commonly used to treat Mycobacterium avium complex infection in HIV patients?

• A. Rifabutin
• B. Ethambutol
• C. Clarithromycin
• D. Rifampin

Answer: (C)

Disseminated Mycobacterium avium complex disease in HIV patients is treated with a regimen that centers on a macrolide antibiotic because these drugs penetrate macrophages where MAC hides and provide strong intracellular activity. Clarithromycin is a macrolide that inhibits protein synthesis by binding to the 50S ribosomal subunit, giving it potent activity against MAC. Because MAC can develop resistance if treated with a single drug, clarithromycin is used in combination with other agents—typically ethambutol and often a rifamycin such as rifabutin—to boost effectiveness and reduce resistance risk. Among the options, clarithromycin stands out as the most commonly used agent for MAC treatment due to its proven efficacy, reliable intracellular action, and solid treatment data guiding standard regimens. Rifamycins can be included but have notable interactions with HIV therapies, and ethambutol is important for synergy but less potent on its own.

Disseminated Mycobacterium avium complex disease in HIV patients is treated with a regimen that centers on a macrolide antibiotic because these drugs penetrate macrophages where MAC hides and provide strong intracellular activity. Clarithromycin is a macrolide that inhibits protein synthesis by binding to the 50S ribosomal subunit, giving it potent activity against MAC. Because MAC can develop resistance if treated with a single drug, clarithromycin is used in combination with other agents—typically ethambutol and often a rifamycin such as rifabutin—to boost effectiveness and reduce resistance risk. Among the options, clarithromycin stands out as the most commonly used agent for MAC treatment due to its proven efficacy, reliable intracellular action, and solid treatment data guiding standard regimens. Rifamycins can be included but have notable interactions with HIV therapies, and ethambutol is important for synergy but less potent on its own.